NEXGARD SPECTRA has been shown to be safe and effective in various breeds of dogs (including sensitive Collie breeds) when used as directed, and can be given to puppies from 8 weeks of age, providing they weigh at least 2 kg. NEXGARD SPECTRA contains the active ingredient afoxolaner, which has been developed specifically for dogs. All medicines, including veterinary medicines, carry benefits and risks. Afoxolaner was developed specifically for dogs. Afoxolaner is part of the isoxazoline family of chemicals. Adverse reactions to this family of chemicals are rarely observed but may include vomiting, diarrhoea, lethargy, inappetence (loss of appetite), itching and very rarely, seizures. Most adverse reactions are mild, self-limiting and of short duration. For dogs with a history of epilepsy or other seizure disorders, it is recommended to seek veterinary advice prior to treatment with medicines of this class. Robust and extensive safety studies demonstrate Nex. Gard's Spectra excellent safety profile. This is further supported by our rigorous pharamacovigilance program which closely monitors and evaluates any suspected adverse events reported to the company by pet owners or veterinarians in all countries where the product is registered. If you believe your dog has reacted unexpectedly following ingestion of NEXGARD SPECTRA please speak to your veterinarian and contact Boehringer Ingelheim Animal Health Customer Care on 1800 808 691.